Literature DB >> 30138945

Survival after Aortic Valve Replacement for Aortic Regurgitation: Prediction from Preoperative Contractility Measurement.

Jeffrey S Borer1, Phyllis G Supino1, Edmund McM Herrold1, Antony Innasimuthu1, Clare Hochreiter2, Karl Krieger2, Leonard N Girardi2, O Wayne Isom2.   

Abstract

BACKGROUND: Noninvasive measurement of myocardial contractility (end-systolic wall stress-adjusted change in left ventricular ejection fraction from rest to exercise [ΔLVEF - ΔESS]) predicts heart failure, subnormal LVEFrest, and sudden death in asymptomatic patients with chronic severe aortic regurgitation (AR). Here we assess the relation of preoperative ΔLVEF - ΔESS to survival after aortic valve replacement (AVR).
METHODS: Patients who underwent AVR for chronic, isolated, pure severe AR (n = 66) were followed for 13.0 ± 6.4 event-free years. Preoperative ΔLVEF - ΔESS (from combined echocardiographic and radionuclide cineangiographic data) enabled cohort stratification into 3 terciles (-1 to -11% [normal or mild] contractility deficit, -12 to -16% [moderate], and ≤-17% [severe], identical with segregation in our earlier study) to relate preoperative contractility to postoperative survival and to age- and gender-matched US census data.
RESULTS: Since AVR, 22 patients died (average annual risk [AAR] for all-cause mortality for the entire co hort = 3.15%). Preoperative ΔLVEF - ΔESS predicted postoperative survival (p = 0.009, log rank test). By contractility terciles, all-cause AARs were 1.44, 2.58, and 6.40%. Survival was lower than among US census comparators (p < 0.02), but the "mild" tercile was indistinguishable from census data (p = ns). By multivariable Cox regression, survival prediction by pre-AVR ΔLVEF - ΔESS was independent of, and superior to, prediction by age at surgery, gender, preoperative functional class, LVEFrest, LVEFexercise, change in LVEFrest to exercise, and LV diastolic or systolic dimensions (p ≤ 0.01, pre-AVR ΔLVEF - ΔESS vs. other covariates).
CONCLUSION: In severe AR, preoperative contractility predicts post-AVR survival and may be prognostically superior to clinical, geometric and performance descriptors, potentially impacting on patient selection for surgery.
© 2018 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Exercise testing; Radionuclide cineangiography; Valvular heart disease

Mesh:

Year:  2018        PMID: 30138945      PMCID: PMC6262682          DOI: 10.1159/000490848

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  51 in total

1.  Reversal of left ventricular dilatation, hypertrophy, and dysfunction by valve replacement in aortic regurgitation.

Authors:  M J Roman; L Klein; R B Devereux; P Kligfield; N W Niles; C Hochreiter; O W Isom; J S Borer
Journal:  Am Heart J       Date:  1989-09       Impact factor: 4.749

2.  Afterload reduction in chronic aortic regurgitation: it sure seems like a good idea.

Authors:  Thomas M Bashore
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

3.  Incremental Prognostic Utility of Left Ventricular Global Longitudinal Strain in Asymptomatic Patients With Significant Chronic Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction.

Authors:  Alaa Alashi; Amgad Mentias; Amjad Abdallah; Ke Feng; A Marc Gillinov; L Leonardo Rodriguez; Douglas R Johnston; Lars G Svensson; Zoran B Popovic; Brian P Griffin; Milind Y Desai
Journal:  JACC Cardiovasc Imaging       Date:  2017-06-14

4.  Aortic root dilatation as a cause of isolated, severe aortic regurgitation. Prevalence, clinical and echocardiographic patterns, and relation to left ventricular hypertrophy and function.

Authors:  M J Roman; R B Devereux; N W Niles; C Hochreiter; P Kligfield; N Sato; M C Spitzer; J S Borer
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

5.  Hemodynamic predictors of outcome in patients undergoing valve replacement.

Authors:  B A Carabello; H Williams; A K Gash; R Kent; D Belber; A Maurer; J Siegel; K Blasius; J F Spann
Journal:  Circulation       Date:  1986-12       Impact factor: 29.690

6.  Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement.

Authors:  R Forman; B G Firth; M S Barnard
Journal:  Am J Cardiol       Date:  1980-06       Impact factor: 2.778

7.  Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload.

Authors:  Jeffrey S Borer; Sharada Truter; Edmund M Herrold; Domenick J Falcone; Magda Pena; John N Carter; Themy F Dumlao; Jennifer A Lee; Phyllis G Supino
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

8.  Aortic valve replacement: determinants of operative mortality.

Authors:  G W He; T E Acuff; W H Ryan; M B Douthit; R T Bowman; Y H He; M J Mack
Journal:  Ann Thorac Surg       Date:  1994-05       Impact factor: 4.330

9.  Preoperative M-mode echocardiography as a predictor of surgical results in chronic aortic insufficiency.

Authors:  C L Cunha; E R Giuliani; V Fuster; J B Seward; R O Brandenburg; D C McGoon
Journal:  J Thorac Cardiovasc Surg       Date:  1980-02       Impact factor: 5.209

10.  Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function.

Authors:  R O Bonow; E Lakatos; B J Maron; S E Epstein
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

View more
  2 in total

1.  The Evolving Epidemiology of Elderly with Degenerative Valvular Heart Disease: The Guangzhou (China) Heart Study.

Authors:  Shangfei He; Hai Deng; Junrong Jiang; Fangzhou Liu; Hongtao Liao; Yumei Xue; Murui Zheng; Huoxing Li; Shulin Wu
Journal:  Biomed Res Int       Date:  2021-04-23       Impact factor: 3.411

2.  Unplanned Surgery After Transcatheter Closure of Ventricular Septal Defect in Children: Causes and Risk Factors.

Authors:  Penghui Yang; Zhijun Wu; Zhiyuan Liu; Jing Zhang; Hao Zhou; Xiaojuan Ji; Qijian Yi; Mi Li
Journal:  Front Pediatr       Date:  2021-11-30       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.